目的 分析西安交通大学第一附属医院新型抗肿瘤药物的使用情况，探讨医改政策下医院新型抗肿瘤药物的发展趋势，为新型抗肿瘤药物合理使用和规范化管理提供参考。方法 对2019—2021年西安交通大学第一附属医院新型抗肿瘤药物的药品规格、年销售数量、年销售金额、限定日剂量（DDD）、用药频度（DDDs）、日均费用（DDC）以及排序比（B/A）等进行统计分析。结果 2019—2021年西安交通大学第一附属医院新型抗肿瘤药物增加至48个品种，总体销售金额呈逐年增长的趋势。吉非替尼（易瑞沙）与伊马替尼作为临床一线小分子靶向药物，使用频率较大、其DDC最低，B/A 3年均大于2，显示出良好的同步性。奥希替尼（泰瑞沙）用量增长较快、价格较其他小分子靶向药物高，因此销售金额连续2年排名第1名，但因其价格较高，B/A值仅为0.3，同步性较差。大分子单克隆抗体药物曲妥珠单抗（赫赛汀）连续3年销售金额排名第1名，DDC值从2019年330.5元降至2021年250.0元，连续3年B/A为1；贝伐珠单抗（安可达与达攸同）作为国产新型抗肿瘤药物，比进口贝伐珠单抗（安维汀）使用量高、DDDs大、DDC低。结论 西安交通大学第一附属医院新型抗肿瘤药物可供临床使用的品种快速增多。新医改政策实施以来，新型抗肿瘤药物价格下降明显，国家谈判药物以及“4＋7”药物年使用量逐渐增加，符合国家政策要求趋势及当前肿瘤治疗的实际。

Objective To analyze the application situation of new antitumor drugs in the First Affiliated Hospital of Xi’an Jiaotong University, investigate the development tendency of new antitumor drugs in hospitals under the medical reform policy, and provide references for the rational use and standardized management of new antitumor drugs. Methods The new antitumor drugs used in the First Affiliated Hospital of Xi’an Jiaotong University from 2019 to 2021 were analyzed statistically in respect of drug specifications, annual sales volume, annual consumption sums, defined daily dose (DDD), medication frequency (DDDs), average daily cost (DDC) and the ranking ratio (B/A) of new antitumor drugs. Results The number of new anti-tumor drugs increased to 48 varieties from 2019 to 2021, and the consumption sums were increasing year by year in the First Affiliated Hospital of Xi’an Jiaotong University. Gefitinib (Iressa) and Imatinib were clinical first-line small-molecule targeted drugs with high frequency of use, the lowest DDC, and B/A greater than 2 in three years, shows good synchronization. Osimertinib (Taressa) has grown rapidly in dosage and its price is higher than other small molecule targeted drugs, so its sales amount has ranked first for two consecutive years, shows poor synchronizationhas. The trastuzumab was a macromolecular monoclonal antibody drug with the highest frequency of clinical use for three consecutive years. The DDC value has dropped from 330.5 yuan in 2019 to 250.0 yuan in 2021, and the B/A = 1 for three consecutive years. bevacizumab (Ankeda and Dayoutong), as new domestic anti-tumor drugs, have higher usage , larger DDDs, lower DDC than imported bevacizumab (Avastin). Conclusion The varieties of new anti-tumor drugs available for clinical use in the First Affiliated Hospital of Xi'an Jiaotong University are increasing rapidly. Since the implementation of the new medical reform policy, the price of new anti-tumor drugs has been dropped significantly, and the annual usage of nationally negotiated drugs and “4 + 7” drugs has been gradually increasing, which is in accord with the tendency of national policy requirements and the reality of current tumor treatment.

R979.1

陕西省重点研发计划项目(2020SF-210)